Use of SU11248 to inhibit proangiogenic growth factors in renal-cell carcinoma patients
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
Renal-cell carcinoma (RCC) is a highly resistant malignancy in which there is high expression of proangiogenic vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) due to loss of von Hippel-Lindau tumor suppressor gene activity. Blockade of VEGF and PDGF signaling pathways might inhibit tumor growth. In a multicenter phase II study, Motzer et al. tested whether SU11248 (sunitinib malate), which selectively inhibits tyrosine kinases required for signaling by VEGF and PDGF receptors, had antitumor activity in metastatic RCC.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.